IGFBP-2 mRNA was detected in all ovarian specimens and was 2- to 30-fold higher in malignant than in benign neoplasms.
In order to clarify the molecular relationships among the spectrum of serous ovarian tumors, we compared gene expression profiles of 7 LMP and 28 invasive (moderate and poorly differentiated or Grade 2 and Grade 3) serous ovarian tumors with two different reference groups: 7 serous benign ovarian tumors and four normal whole ovary specimens.
Using immunohistochemistry, we examined the protein expression of paraffin-embedded specimens from 140 patients with epithelial ovarian cancer, 20 cases with borderline ovarian tumours, 20 cases with benign ovarian tumours, and 20 cases with normal ovarian tissues.
Although EpCAM-positive exosomes were present in both patients with benign ovarian disease and those harboring ovarian cancer, exosomal miRNA from ovarian cancer patients displayed similar profiles and were considerably distinct from those observed in benign cases.
Results: Two hundred twenty-six malignant, 171 benign pelvic tumors (of which 129 were benign ovarian tumors), and 15 borderline tumors were evaluated.
We investigated five ovarian carcinomas, one borderline tumour, one benign ovarian teratoma and one normal ovary.
Two normal ovaries, one benign ovarian adenoma and one ovarian endometriotic cyst were tested as non-malignant controls.
IHC on ovarian TMA constructs of normal ovarian epithelium, benign ovarian cysts, and early and late OECs showed that E2F5 expression was completely absent in all normal and benign samples tested.
To assess ovarian cortex surrounding benign ovarian cysts after cryopreservation and grafting to severe combined immunodeficient (SCID) mice.
